anurajms/meta_analysis huggingface dataset:
MESH terms:
Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus
1. *Blood Glucose; 2. Diabetes Mellitus, Type 1 [blood, complications, *drug therapy]; 3. Diabetic Nephropathies [prevention & control]; 4. Diabetic Neuropathies [prevention & control]; 5. Diabetic Retinopathy [prevention & control]; 6. Glycated Hemoglobin [metabolism]; 7. Hyperglycemia [chemically induced]; 8. Hypoglycemic Agents [administration & dosage]; 9. Insulin [administration & dosage]; 10. Ketosis [chemically induced]; 11. Randomized Controlled Trials as Topic;
MESH terms:
Transtheoretical model stages of change for dietary and physical exercise modification in weight loss management for overweight and obese adults
1. *Diet, Reducing; 2. *Exercise; 3. *Models, Psychological; 4. *Weight Loss; 5. Health Behavior; 6. Obesity [psychology, *therapy]; 7. Overweight [psychology, therapy]; 8. Randomized Controlled Trials as Topic;
MESH terms:
Vitamin D supplementation for prevention of mortality in adults
1. *Mortality; 2. Calcitriol [*therapeutic use]; 3. Cause of Death; 4. Cholecalciferol [*therapeutic use]; 5. Dietary Supplements; 6. Ergocalciferols [*therapeutic use]; 7. Hydroxycholecalciferols [*therapeutic use]; 8. Randomized Controlled Trials as Topic; 9. Vitamins [*therapeutic use];
MESH terms:
Blue‐light filtering spectacle lenses for visual performance, sleep, and macular health in adults
1. *Asthenopia; 2. *Drug-Related Side Effects and Adverse Reactions; 3. Eyeglasses; 4. Light; 5. *Melatonin; 6. Sleep;
MESH terms:
Laser‐assisted cataract surgery versus standard ultrasound phacoemulsification cataract surgery
1. *Cataract [complications]; 2. *Cataract Extraction [adverse effects]; 3. Lasers; 4. *Macular Edema [etiology]; 5. *Phacoemulsification [adverse effects, methods];
MESH terms:
Antibiotics versus placebo for acute bacterial conjunctivitis
1. *Anti-Bacterial Agents [adverse effects]; 2. *Conjunctivitis, Bacterial [drug therapy]; 3. Randomized Controlled Trials as Topic;
MESH terms:
Device‐modified trabeculectomy for glaucoma
1. *Cataract; 2. *Glaucoma [surgery]; 3. Intraocular Pressure; 4. Quality of Life; 5. Randomized Controlled Trials as Topic; 6. *Trabeculectomy [methods];
MESH terms:
Lens extraction versus laser peripheral iridotomy for acute primary angle closure
1. *Cataract Extraction [adverse effects]; 2. *Glaucoma [surgery]; 3. Intraocular Pressure; 4. *Phacoemulsification [adverse effects, methods]; 5. Quality of Life;
MESH terms:
Interventions for acute non‐arteritic central retinal artery occlusion
1. Anticoagulants [therapeutic use]; 2. China; 3. *Retinal Artery Occlusion [therapy]; 4. *Tissue Plasminogen Activator [therapeutic use];
MESH terms:
Trifocal intraocular lenses versus bifocal intraocular lenses after cataract extraction among participants with presbyopia
1. Capsule Opacification; 2. *Cataract Extraction; 3. *Lenses, Intraocular; 4. *Presbyopia [surgery]; 5. Quality of Life; 6. Randomized Controlled Trials as Topic;
MESH terms:
Iridotomy to slow progression of visual field loss in angle‐closure glaucoma
1. *Glaucoma; 2. *Glaucoma, Angle-Closure [surgery]; 3. Intraocular Pressure; 4. Quality of Life; 5. Vision Disorders; 6. Visual Fields;
MESH terms:
Early vitrectomy for exogenous endophthalmitis following surgery
1. Anti-Bacterial Agents [therapeutic use]; 2. *Cataract [drug therapy]; 3. *Cataract Extraction [adverse effects]; 4. *Endophthalmitis [drug therapy, etiology, surgery]; 5. Randomized Controlled Trials as Topic; 6. Vitrectomy [adverse effects, methods];
MESH terms:
Adjunctive steroid therapy versus antibiotics alone for acute endophthalmitis after intraocular procedure
1. Anti-Bacterial Agents [therapeutic use]; 2. Dexamethasone [therapeutic use]; 3. *Endophthalmitis [drug therapy]; 4. *Eye Diseases; 5. *Retinal Detachment; 6. Steroids [therapeutic use];
MESH terms:
Tocilizumab for giant cell arteritis
1. Adrenal Cortex Hormones; 2. Antibodies, Monoclonal, Humanized [adverse effects]; 3. *Giant Cell Arteritis [drug therapy]; 4. Recurrence;
MESH terms:
Immediate sequential bilateral surgery versus delayed sequential bilateral surgery for cataracts
1. *Cataract; 2. *Cataract Extraction [adverse effects, methods]; 3. *Endophthalmitis; 4. Lens Implantation, Intraocular [methods]; 5. Visual Acuity;
MESH terms:
Topical pharmacologic interventions versus placebo for epidemic keratoconjunctivitis
1. *Conjunctivitis [drug therapy]; 2. *Conjunctivitis, Viral [drug therapy]; 3. Cyclosporine [therapeutic use]; 4. Dexamethasone; 5. Fluorometholone; 6. Ganciclovir; 7. *Keratoconjunctivitis [drug therapy]; 8. Levofloxacin; 9. Lubricant Eye Drops [therapeutic use]; 10. Povidone-Iodine; 11. Tacrolimus; 12. Trifluridine;
MESH terms:
Pneumatic retinopexy versus scleral buckle for repairing simple rhegmatogenous retinal detachments
1. Quality of Life; 2. Randomized Controlled Trials as Topic; 3. Retina; 4. *Retinal Detachment [surgery]; 5. Scleral Buckling [adverse effects]; 6. Vitrectomy;
MESH terms:
Fornix‐based versus limbal‐based conjunctival trabeculectomy flaps for glaucoma
1. *Glaucoma [surgery]; 2. *Glaucoma, Open-Angle [surgery]; 3. Intraocular Pressure; 4. Sclera; 5. *Trabeculectomy;
MESH terms:
Intraocular lens optic edge design for the prevention of posterior capsule opacification after cataract surgery
1. Capsule Opacification [etiology, *prevention & control]; 2. Cataract; 3. *Cataract Extraction; 4. Lens Capsule, Crystalline; 5. *Lens Implantation, Intraocular; 6. *Lenses, Intraocular; 7. Phacoemulsification; 8. Postoperative Complications [*prevention & control]; 9. *Prosthesis Design;
MESH terms:
Adjunctive modulation of wound healing during cataract surgery to promote survival of a previous trabeculectomy
1. *Cataract; 2. *Cataract Extraction; 3. *Glaucoma [surgery]; 4. *Trabeculectomy; 5. Wound Healing;
MESH terms:
Photobiomodulation for non‐exudative age‐related macular degeneration
1. Bias; 2. Confidence Intervals; 3. Contrast Sensitivity; 4. Disease Progression; 5. Low-Level Light Therapy [adverse effects, *methods]; 6. Macular Degeneration [*radiotherapy]; 7. Outcome Assessment, Health Care; 8. Placebos; 9. Quality of Life; 10. Randomized Controlled Trials as Topic; 11. Treatment Outcome; 12. Visual Acuity;
MESH terms:
Surgery for idiopathic epiretinal membrane
1. Bias; 2. Confidence Intervals; 3. Disease Progression; 4. Epiretinal Membrane [*surgery]; 5. *Visual Acuity; 6. *Watchful Waiting;
MESH terms:
Lens extraction for chronic angle‐closure glaucoma
1. Chronic Disease; 2. Disease Progression; 3. Glaucoma, Angle-Closure [drug therapy, *surgery]; 4. Lens, Crystalline [*surgery]; 5. Phacoemulsification [adverse effects, *methods]; 6. Quality of Life; 7. Randomized Controlled Trials as Topic; 8. Visual Acuity;
MESH terms:
Laser peripheral iridoplasty for chronic angle closure
1. Bias; 2. Chronic Disease; 3. Glaucoma, Angle-Closure [drug therapy, *surgery]; 4. Intraocular Pressure; 5. Iris [*surgery]; 6. Laser Therapy [*methods, statistics & numerical data]; 7. Lasers, Gas [therapeutic use]; 8. Randomized Controlled Trials as Topic;
MESH terms:
Ab interno trabecular bypass surgery with Trabectome for open‐angle glaucoma
1. Bias; 2. Glaucoma, Open-Angle [*surgery]; 3. *Phacoemulsification; 4. Randomized Controlled Trials as Topic; 5. Trabecular Meshwork [*surgery]; 6. Trabeculectomy [*instrumentation, methods];
MESH terms:
Wavefront excimer laser refractive surgery for adults with refractive errors
1. Astigmatism [surgery]; 2. Corneal Wavefront Aberration [*surgery]; 3. Hyperopia [surgery]; 4. Keratectomy, Subepithelial, Laser-Assisted [adverse effects, *methods]; 5. Keratomileusis, Laser In Situ [adverse effects, *methods]; 6. Lasers, Excimer [*therapeutic use]; 7. Myopia [surgery]; 8. Photorefractive Keratectomy [adverse effects, *methods]; 9. Randomized Controlled Trials as Topic; 10. Treatment Outcome; 11. Visual Acuity;
MESH terms:
Visual cycle modulators versus placebo or observation for the prevention and treatment of geographic atrophy due to age‐related macular degeneration
1. Choroidal Neovascularization [epidemiology]; 2. Clinical Trials, Phase II as Topic; 3. Disease Progression; 4. Fenretinide [adverse effects, *therapeutic use]; 5. Geographic Atrophy [*drug therapy, etiology, *prevention & control]; 6. Incidence; 7. Macular Degeneration [*complications]; 8. Phenyl Ethers [adverse effects, *therapeutic use]; 9. Placebos [therapeutic use]; 10. Propanolamines [adverse effects, *therapeutic use]; 11. Randomized Controlled Trials as Topic; 12. Visual Acuity [drug effects]; 13. *Watchful Waiting;
MESH terms:
Corneal collagen cross‐linking for bacterial infectious keratitis
1. Anti-Bacterial Agents [therapeutic use]; 2. Collagen [*radiation effects]; 3. Eye Infections, Bacterial [drug therapy, *radiotherapy]; 4. Keratitis [drug therapy, microbiology, *radiotherapy]; 5. Photosensitizing Agents [*therapeutic use]; 6. Randomized Controlled Trials as Topic; 7. Riboflavin [*therapeutic use]; 8. Ultraviolet Therapy [adverse effects, *methods]; 9. Visual Acuity;
MESH terms:
Treatment regimens for administration of anti‐vascular endothelial growth factor agents for neovascular age‐related macular degeneration
1. Angiogenesis Inhibitors [*administration & dosage, economics]; 2. Bevacizumab [administration & dosage, economics]; 3. Bias; 4. Drug Administration Schedule; 5. Endophthalmitis [epidemiology, etiology]; 6. Intravitreal Injections [adverse effects]; 7. Macular Degeneration [*drug therapy, pathology]; 8. Quality of Life; 9. Randomized Controlled Trials as Topic; 10. Ranibizumab [administration & dosage, economics]; 11. Receptors, Vascular Endothelial Growth Factor [administration & dosage]; 12. Recombinant Fusion Proteins [administration & dosage, economics]; 13. Retina [drug effects]; 14. Vascular Endothelial Growth Factor A [*antagonists & inhibitors]; 15. Visual Acuity [*drug effects];
MESH terms:
Laser‐assisted in‐situ keratomileusis (LASIK) with a mechanical microkeratome compared to LASIK with a femtosecond laser for LASIK in adults with myopia or myopic astigmatism
1. Astigmatism [*surgery]; 2. Keratomileusis, Laser In Situ [instrumentation, *methods]; 3. Myopia [*surgery]; 4. Randomized Controlled Trials as Topic; 5. Visual Acuity;
MESH terms:
Intense pulsed light (IPL) therapy for the treatment of meibomian gland dysfunction
1. Dry Eye Syndromes [etiology, therapy]; 2. Intense Pulsed Light Therapy [*methods]; 3. Meibomian Gland Dysfunction [complications, *therapy]; 4. Randomized Controlled Trials as Topic;
MESH terms:
Ab interno trabecular bypass surgery with Schlemm´s canal microstent (Hydrus) for open angle glaucoma
1. *Glaucoma Drainage Implants; 2. Cataract Extraction; 3. Glaucoma, Open‐Angle [*surgery]; 4. Randomized Controlled Trials as Topic; 5. Trabeculectomy [*methods];
MESH terms:
Low vision rehabilitation for better quality of life in visually impaired adults
1. *Quality of Life; 2. Depression [therapy]; 3. Randomized Controlled Trials as Topic; 4. Self Efficacy; 5. Vision, Low [*psychology, *rehabilitation];
MESH terms:
Toric intraocular lens versus limbal relaxing incisions for corneal astigmatism after phacoemulsification
1. *Visual Acuity [physiology]; 2. Astigmatism [etiology, surgery]; 3. Keratoplasty, Penetrating [*methods]; 4. Lens Implantation, Intraocular [*methods]; 5. Lenses, Intraocular; 6. Phacoemulsification [*methods]; 7. Postoperative Complications [epidemiology]; 8. Randomized Controlled Trials as Topic; 9. Refraction, Ocular [physiology];
MESH terms:
Pars plana vitrectomy combined with scleral buckle versus pars plana vitrectomy for giant retinal tear
1. Randomized Controlled Trials as Topic; 2. Retinal Detachment [*surgery]; 3. Retinal Perforations [*surgery]; 4. Scleral Buckling [*methods]; 5. Treatment Outcome; 6. Vitrectomy [*methods];
MESH terms:
Topical cyclosporine A therapy for dry eye syndrome
1. Cyclosporine [*administration & dosage, therapeutic use]; 2. Dry Eye Syndromes [*drug therapy]; 3. Lubricant Eye Drops [*administration & dosage, therapeutic use]; 4. Randomized Controlled Trials as Topic;
MESH terms:
Conventional occlusion versus pharmacologic penalization for amblyopia
1. Amblyopia [*therapy]; 2. Atropine [*therapeutic use]; 3. Occlusive Dressings; 4. Ophthalmic Solutions [*therapeutic use]; 5. Randomized Controlled Trials as Topic; 6. Visual Acuity;
MESH terms:
Intrastromal corneal ring segments for treating keratoconus
1. Corneal Stroma [*surgery]; 2. Corneal Transplantation [methods]; 3. Keratoconus [*surgery]; 4. Prostheses and Implants; 5. Prosthesis Implantation [*methods];
MESH terms:
Aqueous shunts with mitomycin C versus aqueous shunts alone for glaucoma
1. *Glaucoma Drainage Implants; 2. Glaucoma [surgery, *therapy]; 3. Mitomycin [*therapeutic use]; 4. Randomized Controlled Trials as Topic; 5. Treatment Outcome;
MESH terms:
Ab interno trabecular bypass surgery with iStent for open‐angle glaucoma
1. Antihypertensive Agents [administration & dosage]; 2. Combined Modality Therapy [methods]; 3. *Glaucoma Drainage Implants; 4. Glaucoma, Open-Angle [*surgery]; 5. Ocular Hypertension [therapy]; 6. Ophthalmic Solutions [administration & dosage]; 7. Phacoemulsification; 8. Randomized Controlled Trials as Topic; 9. *Stents; 10. *Trabecular Meshwork;
MESH terms:
Cyclodestructive procedures for refractory glaucoma
1. *Glaucoma Drainage Implants [adverse effects]; 2. Aqueous Humor; 3. Ciliary Body [*surgery]; 4. Endoscopy; 5. Glaucoma [*surgery]; 6. Intraocular Pressure; 7. Laser Coagulation [adverse effects, *methods]; 8. Lasers, Solid‐State [therapeutic use]; 9. Randomized Controlled Trials as Topic; 10. Visual Acuity;
MESH terms:
Pars plana vitrectomy versus scleral buckling for repairing simple rhegmatogenous retinal detachments
1. *Scleral Buckling [adverse effects, statistics & numerical data]; 2. *Vitrectomy [adverse effects, statistics & numerical data]; 3. Postoperative Complications; 4. Quality of Life; 5. Randomized Controlled Trials as Topic; 6. Recurrence; 7. Retinal Detachment [etiology, *surgery]; 8. Retinal Perforations [*complications]; 9. Treatment Outcome; 10. Visual Acuity;
MESH terms:
Endoscopic cyclophotocoagulation (ECP) for open angle glaucoma and primary angle closure
1. *Endoscopy; 2. Combined Modality Therapy [methods]; 3. Glaucoma, Angle‐Closure [*surgery]; 4. Glaucoma, Open‐Angle [*surgery]; 5. Laser Coagulation [*methods]; 6. Phacoemulsification;
MESH terms:
Routine preoperative medical testing for cataract surgery
1. Age Factors; 2. Cataract Extraction [*adverse effects, *economics, statistics & numerical data]; 3. Cost Savings; 4. Diagnostic Tests, Routine [*economics]; 5. Hospitalization [statistics & numerical data]; 6. Intraoperative Complications [epidemiology, prevention & control]; 7. Postoperative Complications [epidemiology, prevention & control]; 8. Randomized Controlled Trials as Topic;
MESH terms:
Anti‐tumour necrosis factor biological therapies for the treatment of uveitic macular oedema (UMO) for non‐infectious uveitis
1. Macular Edema [*drug therapy, etiology]; 2. Off-Label Use; 3. Tumor Necrosis Factor-alpha [*antagonists & inhibitors]; 4. Uveitis [*complications];
MESH terms:
Subconjunctival draining minimally‐invasive glaucoma devices for medically uncontrolled glaucoma
1. *Glaucoma Drainage Implants [adverse effects]; 2. Glaucoma [*therapy]; 3. Intraocular Pressure; 4. Trabeculectomy;
MESH terms:
Descemet's membrane endothelial keratoplasty (DMEK) versus Descemet's stripping automated endothelial keratoplasty (DSAEK) for corneal endothelial failure
1. *Descemet Stripping Endothelial Keratoplasty [adverse effects]; 2. Cell Count; 3. Corneal Diseases [*surgery]; 4. Corneal Transplantation; 5. Descemet Membrane [*surgery]; 6. Endothelial Cells [cytology]; 7. Fuchs' Endothelial Dystrophy [*surgery]; 8. Non‐Randomized Controlled Trials as Topic; 9. Postoperative Complications [etiology]; 10. Visual Acuity;
MESH terms:
Blue‐light filtering intraocular lenses (IOLs) for protecting macular health
1. *Cataract Extraction [adverse effects, statistics & numerical data]; 2. *Lenses, Intraocular; 3. *Light; 4. Color; 5. Contrast Sensitivity; 6. Filtration [*instrumentation]; 7. Macula Lutea [*radiation effects]; 8. Macular Degeneration [*prevention & control]; 9. Postoperative Complications [*prevention & control]; 10. Randomized Controlled Trials as Topic;
MESH terms:
Reading aids for adults with low vision
1. *Reading; 2. *Sensory Aids; 3. Eyeglasses; 4. Lenses; 5. Macular Degeneration [complications]; 6. Optical Devices [*standards]; 7. Randomized Controlled Trials as Topic; 8. Vision, Low [etiology, *rehabilitation]; 9. Visual Acuity; 10. Visually Impaired Persons [*rehabilitation];
MESH terms:
Optical correction of refractive error for preventing and treating eye symptoms in computer users
1. *Computer Terminals; 2. *Eyeglasses; 3. Asthenopia [etiology, *prevention & control]; 4. Ergonomics; 5. Headache [prevention & control]; 6. Randomized Controlled Trials as Topic; 7. Refractive Errors [*therapy];
MESH terms:
Adjustable versus non‐adjustable sutures for strabismus
1. *Suture Techniques; 2. Strabismus [*surgery]; 3. Treatment Outcome;
MESH terms:
Interventions to increase attendance for diabetic retinopathy screening
1. *Quality Improvement [economics]; 2. Costs and Cost Analysis; 3. Diabetes Mellitus, Type 1 [*complications]; 4. Diabetes Mellitus, Type 2 [*complications]; 5. Diabetic Retinopathy [*diagnosis]; 6. Patient Compliance [psychology, *statistics & numerical data]; 7. Randomized Controlled Trials as Topic;
MESH terms:
Anti‐vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity
1. Angiogenesis Inhibitors [*administration & dosage, adverse effects]; 2. Aptamers, Nucleotide [*administration & dosage, adverse effects]; 3. Bevacizumab [*administration & dosage, adverse effects]; 4. Combined Modality Therapy; 5. Cryotherapy [methods]; 6. Intravitreal Injections; 7. Laser Therapy [methods]; 8. Randomized Controlled Trials as Topic; 9. Ranibizumab [*administration & dosage, adverse effects]; 10. Retinal Detachment [prevention & control]; 11. Retinopathy of Prematurity [*drug therapy]; 12. Vascular Endothelial Growth Factor A [*antagonists & inhibitors];
MESH terms:
Surgical interventions for vertical strabismus in superior oblique palsy
1. *Oculomotor Muscles; 2. Ophthalmoplegia [*complications]; 3. Postoperative Complications; 4. Randomized Controlled Trials as Topic; 5. Strabismus [etiology, *surgery];
MESH terms:
Interventions to improve access to cataract surgical services and their impact on equity in low‐ and middle‐income countries
1. *Cataract Extraction; 2. *Developing Countries; 3. *Health Services Accessibility [statistics & numerical data]; 4. *Rural Health Services; 5. Cataract [complications]; 6. China; 7. Patient Education as Topic; 8. Randomized Controlled Trials as Topic; 9. Referral and Consultation [statistics & numerical data]; 10. Vision Disorders;
MESH terms:
Ocriplasmin for symptomatic vitreomacular adhesion
1. *Vitreous Body; 2. Fibrinolysin [*administration & dosage, adverse effects]; 3. Fibrinolytic Agents [*administration & dosage, adverse effects]; 4. Intravitreal Injections; 5. Peptide Fragments [*administration & dosage, adverse effects]; 6. Randomized Controlled Trials as Topic; 7. Retinal Diseases [*drug therapy]; 8. Time Factors; 9. Tissue Adhesions [drug therapy]; 10. Visual Acuity; 11. Vitrectomy; 12. Vitreous Detachment [drug therapy, etiology];
MESH terms:
Different‐sized incisions for phacoemulsification in age‐related cataract
1. *Cataract; 2. *Surgical Wound; 3. Astigmatism [*etiology]; 4. Corneal Edema [etiology]; 5. Corneal Pachymetry; 6. Phacoemulsification [adverse effects, *methods]; 7. Postoperative Complications [*etiology]; 8. Randomized Controlled Trials as Topic; 9. Visual Acuity;
MESH terms:
Aqueous shunts for glaucoma
1. *Glaucoma Drainage Implants [adverse effects]; 2. *Intraocular Pressure; 3. Cataract Extraction; 4. Glaucoma [*surgery]; 5. Molteno Implants [adverse effects]; 6. Ocular Hypertension [surgery]; 7. Randomized Controlled Trials as Topic; 8. Trabeculectomy;
MESH terms:
Probing for congenital nasolacrimal duct obstruction
1. Age Factors; 2. Anti‐Bacterial Agents [therapeutic use]; 3. Cost‐Benefit Analysis; 4. Dacryocystorhinostomy [adverse effects, economics, instrumentation, *methods]; 5. Lacrimal Duct Obstruction [*congenital, *therapy]; 6. Massage; 7. Randomized Controlled Trials as Topic; 8. Remission, Spontaneous; 9. Reoperation [statistics & numerical data]; 10. Surgical Instruments; 11. Time Factors; 12. Watchful Waiting;
MESH terms:
Non‐steroidal anti‐inflammatory drugs versus corticosteroids for controlling inflammation after uncomplicated cataract surgery
1. *Phacoemulsification [adverse effects]; 2. Adrenal Cortex Hormones [*therapeutic use]; 3. Anti‐Inflammatory Agents, Non‐Steroidal [*therapeutic use]; 4. Cataract Extraction [*adverse effects, *methods]; 5. Corneal Edema [etiology, prevention & control]; 6. Drug Therapy, Combination; 7. Eye Diseases [etiology, *prevention & control]; 8. Inflammation [etiology, prevention & control]; 9. Macular Edema [etiology, prevention & control]; 10. Postoperative Complications [etiology, *prevention & control]; 11. Randomized Controlled Trials as Topic; 12. Visual Acuity;
MESH terms:
Nd:YAG laser vitreolysis versus pars plana vitrectomy for vitreous floaters
1. Eye Diseases [*surgery]; 2. Lasers, Solid‐State [*therapeutic use]; 3. Vitrectomy [*methods];
MESH terms:
Topical non‐steroidal anti‐inflammatory drugs for analgesia in traumatic corneal abrasions
1. Administration, Topical; 2. Anti‐Inflammatory Agents, Non‐Steroidal [*administration & dosage, adverse effects]; 3. Corneal Injuries [complications, *drug therapy]; 4. Diclofenac [administration & dosage]; 5. Flurbiprofen [administration & dosage]; 6. Indomethacin [administration & dosage]; 7. Ketorolac [administration & dosage]; 8. Pain Measurement; 9. Randomized Controlled Trials as Topic; 10. Wound Healing;
MESH terms:
Autologous serum eye drops for dry eye
1. *Serum; 2. Dry Eye Syndromes [*therapy]; 3. Lubricant Eye Drops [*administration & dosage]; 4. Ophthalmic Solutions [therapeutic use]; 5. Randomized Controlled Trials as Topic; 6. Sodium Chloride [therapeutic use]; 7. Tears [physiology];
MESH terms:
N‐acetylcarnosine (NAC) drops for age‐related cataract
1. Aging; 2. Carnosine [administration & dosage, *analogs & derivatives]; 3. Cataract [*drug therapy, etiology]; 4. Disease Progression; 5. Ophthalmic Solutions [administration & dosage]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Endonasal versus external dacryocystorhinostomy for nasolacrimal duct obstruction
1. Blood Loss, Surgical; 2. Dacryocystorhinostomy [adverse effects, *methods]; 3. Laser Therapy [methods]; 4. Postoperative Hemorrhage [etiology]; 5. Randomized Controlled Trials as Topic; 6. Surgical Wound Infection [etiology]; 7. Treatment Failure;
MESH terms:
Perioperative medications for preventing temporarily increased intraocular pressure after laser trabeculoplasty
1. Adrenergic alpha‐2 Receptor Agonists [therapeutic use]; 2. Antihypertensive Agents [adverse effects, *therapeutic use]; 3. Brimonidine Tartrate [therapeutic use]; 4. Clonidine [analogs & derivatives, therapeutic use]; 5. Conjunctiva [drug effects]; 6. Glaucoma, Open‐Angle [*surgery]; 7. Intraocular Pressure [*drug effects]; 8. Ocular Hypertension [*prevention & control]; 9. Pilocarpine [therapeutic use]; 10. Postoperative Complications [*prevention & control]; 11. Randomized Controlled Trials as Topic; 12. Trabeculectomy [*adverse effects];
MESH terms:
Topical medication instillation techniques for glaucoma
1. Administration, Ophthalmic; 2. Antihypertensive Agents [*administration & dosage, adverse effects]; 3. Bimatoprost [administration & dosage]; 4. Eyelashes [anatomy & histology, drug effects]; 5. Glaucoma [*drug therapy]; 6. Intraocular Pressure [*drug effects]; 7. Latanoprost; 8. Ophthalmic Solutions [administration & dosage, adverse effects]; 9. Prostaglandins F, Synthetic [administration & dosage]; 10. Randomized Controlled Trials as Topic; 11. Travoprost [administration & dosage];
MESH terms:
Surgery for cataracts in people with age‐related macular degeneration
1. Cataract [*complications]; 2. Cataract Extraction [*adverse effects]; 3. Disease Progression; 4. Macular Degeneration [*complications, pathology]; 5. Randomized Controlled Trials as Topic; 6. Time Factors; 7. Visual Acuity;
MESH terms:
Laser‐assisted subepithelial keratectomy (LASEK) versus laser‐assisted in‐situ keratomileusis (LASIK) for correcting myopia
1. Keratectomy, Subepithelial, Laser‐Assisted [adverse effects, *methods]; 2. Keratomileusis, Laser In Situ [adverse effects, *methods]; 3. Myopia [*surgery]; 4. Quality of Life; 5. Randomized Controlled Trials as Topic; 6. Visual Acuity;
MESH terms:
Perioperative antibiotics for prevention of acute endophthalmitis after cataract surgery
1. Acute Disease; 2. Anti‐Bacterial Agents [*administration & dosage]; 3. Cataract Extraction [*adverse effects]; 4. Endophthalmitis [*prevention & control]; 5. Injections, Intraocular [methods]; 6. Ophthalmic Solutions [administration & dosage]; 7. Postoperative Complications [*prevention & control]; 8. Randomized Controlled Trials as Topic; 9. Therapeutic Irrigation [methods]; 10. Visual Acuity;
MESH terms:
Non‐surgical interventions for acute internal hordeolum
1. Acute Disease; 2. Hordeolum [pathology, *therapy];
MESH terms:
Anti‐vascular endothelial growth factor for choroidal neovascularisation in people with pathological myopia
1. *Laser Coagulation; 2. *Photochemotherapy; 3. Angiogenesis Inhibitors [adverse effects, *therapeutic use]; 4. Bevacizumab [therapeutic use]; 5. Choroidal Neovascularization [etiology, *therapy]; 6. Macula Lutea [surgery]; 7. Myopia, Degenerative [*complications]; 8. Photosensitizing Agents [therapeutic use]; 9. Porphyrins [therapeutic use]; 10. Randomized Controlled Trials as Topic; 11. Ranibizumab [therapeutic use]; 12. Receptors, Vascular Endothelial Growth Factor [therapeutic use]; 13. Recombinant Fusion Proteins [therapeutic use]; 14. Vascular Endothelial Growth Factor A [*antagonists & inhibitors]; 15. Verteporfin;
MESH terms:
Multifocal versus monofocal intraocular lenses after cataract extraction
1. *Lenses, Intraocular [psychology]; 2. Cataract Extraction [*rehabilitation]; 3. Contrast Sensitivity [physiology]; 4. Patient Satisfaction; 5. Prosthesis Design; 6. Randomized Controlled Trials as Topic; 7. Vision, Ocular [physiology]; 8. Visual Acuity [*physiology];
MESH terms:
Fibrin glue versus sutures for conjunctival autografting in primary pterygium surgery
1. *Autografts; 2. *Sutures; 3. Conjunctiva [*transplantation]; 4. Fibrin Tissue Adhesive [adverse effects, *therapeutic use]; 5. Pterygium [prevention & control, *surgery]; 6. Randomized Controlled Trials as Topic; 7. Recurrence; 8. Secondary Prevention [*methods]; 9. Tissue Adhesives [adverse effects, *therapeutic use]; 10. Transplantation, Autologous;
MESH terms:
Oral antivirals for preventing recurrent herpes simplex keratitis in people with corneal grafts
1. *Corneal Transplantation; 2. Acyclovir [*administration & dosage]; 3. Administration, Oral; 4. Antiviral Agents [*administration & dosage]; 5. Keratitis, Herpetic [*prevention & control]; 6. Randomized Controlled Trials as Topic; 7. Recurrence; 8. Secondary Prevention [*methods]; 9. Time Factors;
MESH terms:
Valacyclovir versus acyclovir for the treatment of herpes zoster ophthalmicus in immunocompetent patients
1. *Immunocompetence; 2. Acyclovir [adverse effects, *analogs & derivatives, *therapeutic use]; 3. Antiviral Agents [adverse effects, *therapeutic use]; 4. Herpes Zoster Ophthalmicus [*drug therapy, immunology]; 5. Randomized Controlled Trials as Topic; 6. Valacyclovir; 7. Valine [adverse effects, *analogs & derivatives, therapeutic use];
MESH terms:
Integrated versus non‐integrated orbital implants for treating anophthalmic sockets
1. Anophthalmos [etiology, *rehabilitation]; 2. *Durapatite; 3. Eye Enucleation [*rehabilitation]; 4. Eye Evisceration [*rehabilitation]; 5. *Orbital Implants [classification]; 6. *Polyethylene; 7. *Polymethyl Methacrylate; 8. Prosthesis Design; 9. Prosthesis Implantation [*methods]; 10. Randomized Controlled Trials as Topic;
MESH terms:
Prophylactic non‐steroidal anti‐inflammatory drugs for the prevention of macular oedema after cataract surgery
1. Administration, Topical; 2. Anti‐Inflammatory Agents, Non‐Steroidal [adverse effects, *therapeutic use]; 3. Cataract Extraction [*adverse effects]; 4. Macular Edema [etiology, *prevention & control]; 5. Postoperative Complications [*prevention & control]; 6. Randomized Controlled Trials as Topic; 7. Steroids [therapeutic use];
MESH terms:
Statins for age‐related macular degeneration
1. Hydroxymethylglutaryl‐CoA Reductase Inhibitors [adverse effects, *therapeutic use]; 2. Macular Degeneration [*prevention & control]; 3. Randomized Controlled Trials as Topic; 4. Simvastatin [adverse effects, *therapeutic use]; 5. Visual Acuity;
MESH terms:
Patching for corneal abrasion
1. *Occlusive Dressings [adverse effects]; 2. Analgesics [therapeutic use]; 3. Corneal Injuries [*therapy]; 4. Eye Foreign Bodies [complications]; 5. Pain Measurement; 6. Randomized Controlled Trials as Topic; 7. Time Factors; 8. Wound Healing;
MESH terms:
Antibiotics versus no treatment for toxoplasma retinochoroiditis
1. Administration, Oral; 2. Anti‐Bacterial Agents [administration & dosage, *therapeutic use]; 3. Chorioretinitis [*drug therapy, parasitology]; 4. Drug Combinations; 5. Pyrimethamine [therapeutic use]; 6. Randomized Controlled Trials as Topic; 7. Recurrence; 8. Secondary Prevention; 9. Sulfadiazine [therapeutic use]; 10. Sulfamerazine [therapeutic use]; 11. Sulfamethazine [therapeutic use]; 12. Toxoplasmosis, Ocular [complications, *drug therapy]; 13. Trimethoprim, Sulfamethoxazole Drug Combination [administration & dosage, therapeutic use]; 14. Visual Acuity; 15. Watchful Waiting;
MESH terms:
Over the counter (OTC) artificial tear drops for dry eye syndrome
1. Acrylic Resins [administration & dosage]; 2. Dry Eye Syndromes [*drug therapy]; 3. Lubricant Eye Drops [*administration & dosage, chemistry]; 4. Nonprescription Drugs [administration & dosage, chemistry]; 5. Polyvinyl Alcohol [administration & dosage]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Laser‐assisted subepithelial keratectomy (LASEK) versus photorefractive keratectomy (PRK) for correction of myopia
1. *Keratectomy, Subepithelial, Laser‐Assisted [adverse effects]; 2. *Photorefractive Keratectomy [adverse effects]; 3. Myopia [*surgery]; 4. Randomized Controlled Trials as Topic; 5. Time Factors; 6. Visual Acuity;
MESH terms:
Peripheral iridotomy for pigmentary glaucoma
1. Aluminum [therapeutic use]; 2. Antihypertensive Agents [therapeutic use]; 3. Glaucoma, Open-Angle [drug therapy, *surgery]; 4. Intraocular Pressure; 5. Iris [*surgery]; 6. Laser Therapy [adverse effects, *methods]; 7. Ophthalmologic Surgical Procedures; 8. Randomized Controlled Trials as Topic; 9. Visual Acuity; 10. Yttrium [therapeutic use];
MESH terms:
Conjunctival autograft for pterygium
1. *Autografts; 2. Amnion [transplantation]; 3. Conjunctiva [*transplantation]; 4. Pterygium [*surgery]; 5. Randomized Controlled Trials as Topic; 6. Recurrence; 7. Time Factors;
MESH terms:
Aflibercept for neovascular age‐related macular degeneration
1. Angiogenesis Inhibitors [*therapeutic use]; 2. Choroidal Neovascularization [complications, *drug therapy]; 3. Macular Degeneration [*drug therapy, etiology]; 4. Ranibizumab [therapeutic use]; 5. Receptors, Vascular Endothelial Growth Factor [*therapeutic use]; 6. Recombinant Fusion Proteins [*therapeutic use]; 7. Visual Acuity;
MESH terms:
Doxycycline plus ivermectin versus ivermectin alone for treatment of patients with onchocerciasis
1. Doxycycline [adverse effects, *therapeutic use]; 2. Drug Therapy, Combination; 3. Filaricides [adverse effects, *therapeutic use]; 4. Ivermectin [adverse effects, *therapeutic use]; 5. Onchocerciasis [*drug therapy, prevention & control]; 6. Onchocerciasis, Ocular [drug therapy, prevention & control]; 7. Randomized Controlled Trials as Topic; 8. Vision Disorders [prevention & control];
MESH terms:
Anti‐vascular endothelial growth factor for control of wound healing in glaucoma surgery
1. Angiogenesis Inhibitors [*therapeutic use]; 2. Bevacizumab [therapeutic use]; 3. Cicatrix [prevention & control]; 4. Glaucoma [*surgery]; 5. Intraocular Pressure; 6. Mitomycin [therapeutic use]; 7. Randomized Controlled Trials as Topic; 8. Ranibizumab [therapeutic use]; 9. Trabeculectomy [adverse effects]; 10. Vascular Endothelial Growth Factor A [*antagonists & inhibitors]; 11. Wound Healing [*drug effects];
MESH terms:
Interventions for dissociated vertical deviation
1. Oculomotor Muscles [*surgery]; 2. Randomized Controlled Trials as Topic; 3. Strabismus [*surgery]; 4. Treatment Outcome;
MESH terms:
Interventions for trachoma trichiasis
1. Anti‐Bacterial Agents [therapeutic use]; 2. Chlamydia trachomatis; 3. Entropion [etiology, *surgery]; 4. Eyelid Diseases [surgery, *therapy]; 5. Hair Removal [methods]; 6. Randomized Controlled Trials as Topic; 7. Trachoma [surgery, *therapy];
MESH terms:
Mitomycin C versus 5‐Fluorouracil for wound healing in glaucoma surgery
1. *Trabeculectomy; 2. Antimetabolites [*therapeutic use]; 3. Chemotherapy, Adjuvant; 4. Cicatrix [prevention & control]; 5. Fluorouracil [*therapeutic use]; 6. Glaucoma [drug therapy, *surgery]; 7. Intraocular Pressure [drug effects]; 8. Mitomycin [*therapeutic use]; 9. Randomized Controlled Trials as Topic; 10. Risk; 11. Treatment Failure; 12. Wound Healing [*drug effects];
MESH terms:
Day care versus in‐patient surgery for age‐related cataract
1. *Ambulatory Surgical Procedures [economics, methods]; 2. *Cataract Extraction [economics, methods]; 3. *Hospitalization [economics]; 4. Feasibility Studies; 5. Postoperative Complications; 6. Quality of Life; 7. Randomized Controlled Trials as Topic; 8. Visual Acuity;
MESH terms:
Laser treatment of drusen to prevent progression to advanced age‐related macular degeneration
1. Disease Progression; 2. Geographic Atrophy [prevention & control]; 3. Laser Coagulation [methods]; 4. Macular Degeneration [*prevention & control]; 5. Randomized Controlled Trials as Topic; 6. Retinal Drusen [complications, *surgery]; 7. Visual Acuity;
MESH terms:
Intravitreal steroids versus observation for macular edema secondary to central retinal vein occlusion
1. Dexamethasone [administration & dosage]; 2. Intravitreal Injections; 3. Macular Edema [*drug therapy, etiology]; 4. Randomized Controlled Trials as Topic; 5. Retinal Vein Occlusion [*complications]; 6. Steroids [*administration & dosage]; 7. Triamcinolone [administration & dosage]; 8. Visual Acuity; 9. Watchful Waiting;
MESH terms:
Sub‐Tenon's anaesthesia versus topical anaesthesia for cataract surgery
1. *Cataract Extraction; 2. Anesthesia, Local [adverse effects, *methods]; 3. Anesthetics, Local [*administration & dosage]; 4. Nerve Block [*methods]; 5. Pain [etiology]; 6. Pain Measurement; 7. Randomized Controlled Trials as Topic;
MESH terms:
Immunosuppressants for the prophylaxis of corneal graft rejection after penetrating keratoplasty
1. *Keratoplasty, Penetrating; 2. Cyclosporine [therapeutic use]; 3. Graft Rejection [*drug therapy]; 4. Graft Survival; 5. Immunosuppressive Agents [*therapeutic use]; 6. Mycophenolic Acid [analogs & derivatives, therapeutic use]; 7. Randomized Controlled Trials as Topic; 8. Steroids [therapeutic use]; 9. Tacrolimus [therapeutic use];
MESH terms:
Corticosteroids for treating optic neuritis
1. Acute Disease; 2. Administration, Oral; 3. Anti-Inflammatory Agents [administration & dosage, *therapeutic use]; 4. Contrast Sensitivity [drug effects]; 5. Dexamethasone [administration & dosage, therapeutic use]; 6. Glucocorticoids [administration & dosage, *therapeutic use]; 7. Injections, Intravenous; 8. Methylprednisolone [administration & dosage, therapeutic use]; 9. Optic Neuritis [*drug therapy]; 10. Prednisone [administration & dosage, therapeutic use]; 11. Randomized Controlled Trials as Topic; 12. Visual Acuity [drug effects];
MESH terms:
Interventions for idiopathic intracranial hypertension
1. Acetazolamide [*therapeutic use]; 2. Antihypertensive Agents [*therapeutic use]; 3. Cerebrospinal Fluid Pressure [drug effects]; 4. Headache [drug therapy]; 5. Intracranial Hypertension [*therapy]; 6. Randomized Controlled Trials as Topic; 7. Visual Acuity; 8. Weight Loss;
MESH terms:
Combined surgery versus cataract surgery alone for eyes with cataract and glaucoma
1. Cataract [*complications]; 2. Combined Modality Therapy [methods]; 3. Glaucoma [*complications, *surgery]; 4. Intraocular Pressure; 5. Phacoemulsification [adverse effects, *methods]; 6. Randomized Controlled Trials as Topic; 7. Stents; 8. Trabecular Meshwork [surgery]; 9. Trabeculectomy [adverse effects, *methods]; 10. Treatment Outcome;
MESH terms:
Assistive technology for children and young people with low vision
1. *Self‐Help Devices; 2. Vision, Low [*rehabilitation];
MESH terms:
Macular grid laser photocoagulation for branch retinal vein occlusion
1. Anti‐Inflammatory Agents [therapeutic use]; 2. Antibodies, Monoclonal, Humanized [administration & dosage]; 3. Bevacizumab; 4. Laser Coagulation [adverse effects, *methods]; 5. Macular Edema [etiology, *surgery]; 6. Randomized Controlled Trials as Topic; 7. Retinal Vein Occlusion [*complications]; 8. Triamcinolone [administration & dosage]; 9. Visual Acuity [drug effects];
MESH terms:
Medical interventions for fungal keratitis
1. Antifungal Agents [*therapeutic use]; 2. Eye Infections, Fungal [*drug therapy]; 3. Keratitis [*drug therapy, microbiology]; 4. Natamycin [therapeutic use]; 5. Randomized Controlled Trials as Topic; 6. Voriconazole [therapeutic use];
MESH terms:
Surgery for nonarteritic anterior ischemic optic neuropathy
1. Early Termination of Clinical Trials; 2. Optic Neuropathy, Ischemic [*surgery]; 3. Postoperative Complications; 4. Randomized Controlled Trials as Topic; 5. Treatment Failure; 6. Visual Acuity;
MESH terms:
Optical reading aids for children and young people with low vision
1. *Reading; 2. Optical Devices; 3. Vision, Low [*rehabilitation];
MESH terms:
Medical interventions for acanthamoeba keratitis
1. Acanthamoeba Keratitis [*drug therapy]; 2. Anti‐Infective Agents, Local [*therapeutic use]; 3. Biguanides [*therapeutic use]; 4. Chlorhexidine [*therapeutic use]; 5. Randomized Controlled Trials as Topic;
MESH terms:
Face washing promotion for preventing active trachoma
1. *Face; 2. Anti‐Bacterial Agents [administration & dosage]; 3. Australia; 4. Baths [*methods]; 5. Chlamydia trachomatis; 6. Combined Modality Therapy [methods]; 7. Ophthalmic Solutions [therapeutic use]; 8. Randomized Controlled Trials as Topic; 9. Skin Care [*methods]; 10. Tanzania; 11. Tetracycline [administration & dosage]; 12. Trachoma [epidemiology, *prevention & control];
MESH terms:
Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis
1. Administration, Oral; 2. Administration, Topical; 3. Antiviral Agents [*administration & dosage]; 4. Combined Modality Therapy [methods]; 5. Debridement [*methods]; 6. Interferons [administration & dosage]; 7. Keratitis, Herpetic [*therapy]; 8. Randomized Controlled Trials as Topic;
MESH terms:
Interventions for asymptomatic retinal breaks and lattice degeneration for preventing retinal detachment
1. Retinal Degeneration [*therapy]; 2. Retinal Detachment [*prevention & control]; 3. Retinal Perforations [*therapy];
MESH terms:
Excimer laser refractive surgery versus phakic intraocular lenses for the correction of moderate to high myopia
1. *Phakic Intraocular Lenses [adverse effects]; 2. Astigmatism [surgery]; 3. Cataract [etiology]; 4. Lasers, Excimer [adverse effects, *therapeutic use]; 5. Myopia [*surgery]; 6. Randomized Controlled Trials as Topic; 7. Visual Acuity;
MESH terms:
D‐Penicillamine for preventing retinopathy of prematurity in preterm infants
1. Chelating Agents [*therapeutic use]; 2. Infant, Premature; 3. Penicillamine [*therapeutic use]; 4. Randomized Controlled Trials as Topic; 5. Retinopathy of Prematurity [*prevention & control];
MESH terms:
Vitamin D for the treatment of inflammatory bowel disease
1. *Colitis, Ulcerative [drug therapy]; 2. *Crohn Disease [drug therapy]; 3. Neoplasm Recurrence, Local; 4. Recurrence; 5. Remission Induction; 6. Vitamin D [adverse effects];
MESH terms:
Fibrin‐based haemostatic agents for reducing blood loss in adult liver resection
1. Blood Loss, Surgical [prevention & control]; 2. *Fibrin [therapeutic use]; 3. *Hemostatics [therapeutic use]; 4. Liver; 5. Quality of Life;
MESH terms:
Prostaglandins for adult liver transplanted recipients
1. Liver; 2. *Prostaglandins [therapeutic use]; 3. *Quality of Life; 4. Randomized Controlled Trials as Topic;
MESH terms:
Expanded polytetrafluoroethylene (ePTFE)‐covered stents versus bare stents for transjugular intrahepatic portosystemic shunt in people with liver cirrhosis
1. Ascites [etiology, therapy]; 2. Gastrointestinal Hemorrhage [etiology]; 3. *Hepatic Encephalopathy [etiology]; 4. Liver Cirrhosis [complications]; 5. Polytetrafluoroethylene [adverse effects]; 6. *Portasystemic Shunt, Transjugular Intrahepatic [adverse effects, methods]; 7. Quality of Life; 8. Randomized Controlled Trials as Topic; 9. Stents [adverse effects];
MESH terms:
Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis
1. Ammonia; 2. Disaccharides [adverse effects]; 3. *Hepatic Encephalopathy [drug therapy, prevention & control]; 4. Liver Cirrhosis [complications]; 5. Quality of Life; 6. Rifaximin [therapeutic use];
MESH terms:
Fibrin sealants for the prevention of postoperative pancreatic fistula following pancreatic surgery
1. *Fibrin Tissue Adhesive [therapeutic use]; 2. Pancreas [surgery]; 3. Pancreatectomy [adverse effects, methods]; 4. *Pancreatic Fistula [etiology, prevention & control]; 5. Pancreaticoduodenectomy; 6. Postoperative Complications; 7. Randomized Controlled Trials as Topic;
MESH terms:
Granulocyte colony‐stimulating factor with or without stem or progenitor cell or growth factors infusion for people with compensated or decompensated advanced chronic liver disease
1. *Acute-On-Chronic Liver Failure [complications]; 2. *Erythropoietin; 3. *Esophageal and Gastric Varices [complications]; 4. Gastrointestinal Hemorrhage; 5. Granulocyte Colony-Stimulating Factor [therapeutic use]; 6. Growth Hormone; 7. Intercellular Signaling Peptides and Proteins; 8. Liver Cirrhosis [complications]; 9. Quality of Life; 10. Stem Cells;
MESH terms:
Exercise interventions for adults after liver transplantation
1. *Cardiovascular Diseases [prevention & control]; 2. Exercise Therapy [adverse effects]; 3. Fatigue [etiology]; 4. *Liver Transplantation [adverse effects]; 5. *Metabolic Syndrome [complications]; 6. Quality of Life;
MESH terms:
Remote care through telehealth for people with inflammatory bowel disease
1. Chronic Disease; 2. *Colitis, Ulcerative; 3. *COVID-19; 4. *Crohn Disease [therapy]; 5. Neoplasm Recurrence, Local; 6. Quality of Life; 7. *Telemedicine;
MESH terms:
Patient education interventions for the management of inflammatory bowel disease
1. Chronic Disease; 2. *Colitis, Ulcerative [therapy]; 3. *Crohn Disease; 4. *Inflammatory Bowel Diseases [therapy]; 5. Neoplasm Recurrence, Local; 6. Patient Education as Topic; 7. Quality of Life;
MESH terms:
Erythromycin prior to endoscopy for acute upper gastrointestinal haemorrhage
1. Endoscopy; 2. *Erythromycin [adverse effects]; 3. Gastrointestinal Hemorrhage [drug therapy]; 4. *Metoclopramide; 5. Treatment Outcome;
MESH terms:
Interventions to improve sanitation for preventing diarrhoea
1. China; 2. Controlled Before-After Studies; 3. Diarrhea [epidemiology, prevention & control]; 4. *Dysentery; 5. Non-Randomized Controlled Trials as Topic; 6. Randomized Controlled Trials as Topic; 7. *Sanitation;
MESH terms:
Fundoplication in laparoscopic Heller's cardiomyotomy for achalasia
1. *Esophageal Achalasia [surgery]; 2. *Heller Myotomy; 3. *Margins of Excision;
MESH terms:
Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins
1. Anti-Bacterial Agents [therapeutic use]; 2. *Anti-Infective Agents [therapeutic use]; 3. Azithromycin [adverse effects]; 4. Cefixime [therapeutic use]; 5. Ceftriaxone [therapeutic use]; 6. Cephalosporins [therapeutic use]; 7. Chloramphenicol [therapeutic use]; 8. Ciprofloxacin [therapeutic use]; 9. Fluoroquinolones [therapeutic use]; 10. Monobactams [therapeutic use]; 11. Ofloxacin [therapeutic use]; 12. Pakistan; 13. *Paratyphoid Fever [drug therapy]; 14. Recurrence; 15. *Typhoid Fever [drug therapy];
MESH terms:
Electromagnetic‐guided versus endoscopic‐guided postpyloric placement of nasoenteral feeding tubes
1. Cross-Sectional Studies; 2. Electromagnetic Phenomena; 3. *Endoscopy; 4. *Pneumonia; 5. Retrospective Studies;
MESH terms:
Certolizumab pegol for maintenance of medically induced remission in Crohn’s disease
1. *Certolizumab Pegol [adverse effects]; 2. *Crohn Disease [drug therapy]; 3. Inflammation; 4. Randomized Controlled Trials as Topic; 5. Recurrence; 6. Remission Induction;
MESH terms:
Physical activity for treatment of irritable bowel syndrome
1. Abdominal Pain; 2. Exercise; 3. *Irritable Bowel Syndrome [therapy]; 4. Quality of Life; 5. *Yoga;
MESH terms:
Antibiotics for uncomplicated diverticulitis
1. *Anti-Bacterial Agents [therapeutic use]; 2. Colon; 3. *Diverticulitis [drug therapy]; 4. Length of Stay;
MESH terms:
Stem cell transplantation for induction of remission in medically refractory Crohn’s disease
1. Constriction, Pathologic; 2. *Crohn Disease [drug therapy]; 3. *Hematopoietic Stem Cell Transplantation; 4. Inflammation; 5. Remission Induction;
MESH terms:
Tacrolimus (FK506) for induction of remission in corticosteroid‐refractory ulcerative colitis
1. Adrenal Cortex Hormones [therapeutic use]; 2. Beclomethasone; 3. *Colitis, Ulcerative [drug therapy]; 4. Cyclosporine [therapeutic use]; 5. *Proctitis [drug therapy]; 6. Remission Induction; 7. Suppositories; 8. Tacrolimus [therapeutic use];
MESH terms:
Guidewire‐assisted cannulation of the common bile duct for the prevention of post‐endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis
1. Catheterization [adverse effects]; 2. *Cholangiopancreatography, Endoscopic Retrograde [adverse effects, methods]; 3. Common Bile Duct; 4. *Pancreatitis [etiology, prevention & control]; 5. Sphincterotomy, Endoscopic [adverse effects];
MESH terms:
Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding
1. Acute Disease; 2. Endoscopy; 3. Gastrointestinal Hemorrhage [therapy]; 4. *Histamine H2 Antagonists [therapeutic use]; 5. *Proton Pump Inhibitors [therapeutic use];
MESH terms:
Intraperitoneal local anaesthetic instillation versus no intraperitoneal local anaesthetic instillation for laparoscopic cholecystectomy
1. Anesthesia, Local; 2. *Anesthetics, Local; 3. Bupivacaine; 4. *Cholecystectomy, Laparoscopic [adverse effects]; 5. Quality of Life;
MESH terms:
Mesh fixation techniques in primary ventral or incisional hernia repair
1. Fibrin Tissue Adhesive; 2. Hernia, Umbilical [surgery]; 3. Hernia, Ventral [*surgery]; 4. Herniorrhaphy [*methods]; 5. Incisional Hernia [*surgery]; 6. Pain, Postoperative [epidemiology]; 7. Recurrence; 8. Secondary Prevention [methods]; 9. *Surgical Mesh; 10. Sutures; 11. Tissue Adhesives;
MESH terms:
Primary prevention of variceal bleeding in people with oesophageal varices due to liver cirrhosis: a network meta‐analysis
1. Adrenergic beta-Antagonists [adverse effects, therapeutic use]; 2. Bias; 3. Combined Modality Therapy [methods]; 4. Drug Therapy, Combination; 5. Esophageal and Gastric Varices [*complications]; 6. Gastrointestinal Hemorrhage [etiology, *prevention & control]; 7. Ligation; 8. Liver Cirrhosis [*complications]; 9. Network Meta-Analysis; 10. Nitrates [therapeutic use]; 11. Portacaval Shunt, Surgical; 12. *Primary Prevention; 13. Randomized Controlled Trials as Topic; 14. Sclerotherapy;